Pari 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   2 Trials   177 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ColiFin (colistimethate sodium inhalation) / Pari, Spexis
ACTRN12624000601538: Tolerability and Safety of Inhaled Colistimethate Sodium (CMS) Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection (COPILOT)

Not yet recruiting
3
38
 
Spexis Australia Pty Ltd, Spexis Australia Pty Ltd
Cystic Fibrosis , Pseudomonas aeruginosa infection
 
 
2022-000476-18: A study to test how well inhalation of Colistimethate Sodium once a day is tolerated and how safe it is compared with inhalation of Colistimethate Sodium two times a day in adult and children with Cystic Fibrosis and lung infection (COPILOT) Ez a vizsgálat annak tesztelésére szolgál, hogy a kolisztimetát-nátrium napi egyszeri belélegzése mennyire tolerálható, és mennyire biztonságos a kolisztimetát-nátrium napi kétszeri belélegzéséhez képest cisztás fibrózisban és tüdőfertőzésben szenvedő felnőtteknél és gyermekeknél (COPILOT)

Ongoing
3
38
Europe
Colistimethate sodium (CMS), Powder for nebuliser solution, Colfinair 2 MIU Powder for Nebuliser Solution
EnBiotix, Inc., EnBiotix, Inc.
Chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, Chronic lung infections caused by specific bacteria called Pseudomonas aeruginosa in patients with cystic fibrosis., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2021-002335-33: Inhalation therapy in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial Inhalationstherapie bei erwachsenen Bronchiektase-Patienten mit früher asymptomatischer Pseudomonas aeruginosa-Infektion - eine offene, randomisierte Proof of Concept IIT Studie

Not yet recruiting
2
66
Europe
ColiFin, J01X B01, Powder for nebuliser solution, ColiFin(R)
Philipps University Marburg, German Center for Lung Research (DZL), PARI GmbH
bronchiectasis, permanent enlargement of parts of the airways of the lung (bronchiectasis), with inflammatory processes, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ColiFin (colistimethate sodium inhalation) / Pari, Spexis
ACTRN12624000601538: Tolerability and Safety of Inhaled Colistimethate Sodium (CMS) Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection (COPILOT)

Not yet recruiting
3
38
 
Spexis Australia Pty Ltd, Spexis Australia Pty Ltd
Cystic Fibrosis , Pseudomonas aeruginosa infection
 
 
2022-000476-18: A study to test how well inhalation of Colistimethate Sodium once a day is tolerated and how safe it is compared with inhalation of Colistimethate Sodium two times a day in adult and children with Cystic Fibrosis and lung infection (COPILOT) Ez a vizsgálat annak tesztelésére szolgál, hogy a kolisztimetát-nátrium napi egyszeri belélegzése mennyire tolerálható, és mennyire biztonságos a kolisztimetát-nátrium napi kétszeri belélegzéséhez képest cisztás fibrózisban és tüdőfertőzésben szenvedő felnőtteknél és gyermekeknél (COPILOT)

Ongoing
3
38
Europe
Colistimethate sodium (CMS), Powder for nebuliser solution, Colfinair 2 MIU Powder for Nebuliser Solution
EnBiotix, Inc., EnBiotix, Inc.
Chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, Chronic lung infections caused by specific bacteria called Pseudomonas aeruginosa in patients with cystic fibrosis., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2021-002335-33: Inhalation therapy in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial Inhalationstherapie bei erwachsenen Bronchiektase-Patienten mit früher asymptomatischer Pseudomonas aeruginosa-Infektion - eine offene, randomisierte Proof of Concept IIT Studie

Not yet recruiting
2
66
Europe
ColiFin, J01X B01, Powder for nebuliser solution, ColiFin(R)
Philipps University Marburg, German Center for Lung Research (DZL), PARI GmbH
bronchiectasis, permanent enlargement of parts of the airways of the lung (bronchiectasis), with inflammatory processes, Diseases [C] - Respiratory Tract Diseases [C08]
 
 

Download Options